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Abstract
More and more people are concerned by the risk of unexpected side effects observed in the later steps of the development
of new drugs, either in late clinical development or after marketing approval. In order to reduce the risk of the side effects, it
is important to look out for the possible xenobiotic responses at an early stage. We attempt such an effort through a
prediction by assuming that similarities in microarray profiles indicate shared mechanisms of action and/or toxicological
responses among the chemicals being compared. A large time course microarray database derived from livers of
compound-treated rats with thirty-four distinct pharmacological and toxicological responses were studied. The mRMR
(Minimum-Redundancy-Maximum-Relevance) method and IFS (Incremental Feature Selection) were used to select a
compact feature set (141 features) for the reduction of feature dimension and improvement of prediction performance.
With these 141 features, the Leave-one-out cross-validation prediction accuracy of first order response using NNA (Nearest
Neighbor Algorithm) was 63.9%. Our method can be used for pharmacological and xenobiotic responses prediction of new
compounds and accelerate drug development.
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Introduction
Withdrug discoverynowbeingdrivenprimarilybybio-chemistry
and high-throughput screening, the biological effects and, in
particular, the pharmacology and toxicity of new compounds are
required to be studied and evaluated properly before they are
released. However, it is impossible to test every detail of a new
compound in vitro. It is necessary to predict the possible effects of
new drugs, and then experimental examinations can be initiated
and orientated, resulting in a new subject of study – toxicogenomics
[1,2,3,4,5] (combining the toxicology with some high-throughput
technologies) – which enables us to ask some detailed questions
about the possible drug effects very early on, thereby fundamentally
changing the traditional approaches for the drug discovery.
Microarray profiles have been used extensively in some basic
biological researches, biomarker determination, pharmacology,
drug target selectivity, development of prognostic tests and
determination of disease-subclass, as well as in toxicogenomics.
Microarray profile will also be used as the input data of
pharmacological and xenobiotic response for this study. The livers
play many roles in the body functioning, such as the control and
synthesis of critical blood constituents including glucose, free-fatty
acids, ketone bodies, amino acids, hormones, clotting factors, and
inflammatory mediators [6]. The liver is critical in defense against
certain infectious organisms and toxins, entered from the gastroin-
testinal tract [7]. Therefore, data from the liver xenobiotic and
pharmacological responses are used for analysis in the study.
Both the pharmaceutical industry and the Regulatory Author-
ities are, despite the increasing effort to develop safer drugs,
concerned by the risk of unexpected side effects observed in the
later steps of the development of new drugs, either in late clinical
development or after marketing approval. In order to reduce the
risk of the side effects, it is important to look out for the possible
xenobiotic responses at an early stage. We attempt such an effort
through a prediction by assuming that similarities in microarray
profiles indicate shared mechanisms of action and/or toxicological
responses among the chemicals being compared [8,9,10] since it
has been demonstrated that compounds with similar pharmaco-
logical or toxicological effects produced similar gene expression
profiles either in vitro [11] or in vivo [12,13] exposure conditions.
Because one drug may have multiple responses during the
regulatory time-course studies, the prediction should allow one
data to be allocated to multiple classes, i.e. a multiple-target
classification/prediction problem. 34 categories of pharmacolog-
ical and toxicological effects were adopted (Refer to Table 1) to be
the targets of each molecular compound. These categories are
divided according to the body and organ weight (BO), histopa-
thology (H), clinical pathology (CP) and structural activity class
(SAC).
Machine learning and data mining methods have been
widely used in the computational biology and bioinformatics
area. Many researchers have made lots of efforts to develop
useful algorithms and software to investigate various biology
problems such as protein post-translation modification, bio-
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Unique ID Type Category Description Drugs
SV0567082R5RU T CP Absolute monocyte
increase
1-NAPHTHYL ISOTHIOCYANATE, IBUPROFEN, SULINDAC, FLUCONAZOLE, NAPROXEN,
ITRACONAZOLE, 4,49-METHYLENEDIANILINE, ERYTHROMYCIN, GERANIOL,
CHOLECALCIFEROL, OXICONAZOLE, CITRIC ACID, LANSOPRAZOLE, GENTIAN VIOLET,
CHLOROXYLENOL, PRAZIQUANTEL, CARBAMAZEPINE, NYSTATIN, PRAMOXINE, KETOROLAC,
PRALIDOXIME CHLORIDE, BENZETHONIUM CHLORIDE, ROFLUMILAST, IBUFENAC
SV0567098R5RU T CP Creatinine increase IBUPROFEN, NIMESULIDE, CISPLATIN, CHLOROFORM, LOMEFLOXACIN, FLUOXETINE,
PROPYLTHIOURACIL, TICLOPIDINE, PRIMAQUINE, ANISINDIONE, SULFADIAZINE, COLISTIN,
PYROGALLOL, TACRINE, ETODOLAC, ROXITHROMYCIN, AMIODARONE, NAFENOPIN
SV0567149R5RU T CP Albumin increase KETOCONAZOLE, FENOFIBRATE, LOVASTATIN, PREDNISOLONE, PRAVASTATIN,
AMOXAPINE, ISONIAZID, TOLAZAMIDE, DEFERIPRONE, PRIMIDONE, MEGESTROL ACETATE,
PIRINIXIC ACID, BUPROPION, BETAMETHASONE, FLUDROCORTISONE ACETATE,
HYDROCORTISONE, NAFENOPIN
SV0562011R5RU T CP Mean corpuscular
hemoglobin concentration
decrease (diagnostic,
3–7D time points)
CORTISONE, NIMETAZEPAM, THALIDOMIDE, ETODOLAC, ROXITHROMYCIN, ETHISTERONE,
OXYMETHOLONE, 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN, 3-METHYLCHOLANTHRENE,
PHENOBARBITAL, BETA-NAPHTHOFLAVONE, PERHEXILINE, ETHYLESTRENOL, CELECOXIB,
ROFECOXIB, BENOXAPROFEN
SV0571010R5RU T CP Mean corpuscular
hemoglobin concentration
decrease (predictive,
0.25–1D time points)
ROFECOXIB, ETODOLAC, ROXITHROMYCIN, NIMETAZEPAM, CORTISONE, THALIDOMIDE,
OXYMETHOLONE, ETHISTERONE, BETA-NAPHTHOFLAVONE, 3-METHYLCHOLANTHRENE,
2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN, BENOXAPROFEN, ETHYLESTRENOL,
PERHEXILINE, CELECOXIB
SV0567088R5RU T CP Glucose increase KETOCONAZOLE, DEXAMETHASONE, THIOGUANINE, METHOTREXATE, CYCLOSPORIN A,
CARMUSTINE, NAPROXEN, CYPROTERONE ACETATE, PROMAZINE, ISONIAZID,
PYROGALLOL, BETAMETHASONE, HYDROCORTISONE, FLUOCINOLONE ACETONIDE
SV0650093R5RU T H Liver- centrilobular ,
inflammatory cell
infiltrate, mixed cell
ASPIRIN, LEFLUNOMIDE, PENICILLAMINE, CARBOPLATIN, BIS(2-ETHYLHEXYL)PHTHALATE,
CHLOROFORM, CLOFIBRIC ACID, CARBIMAZOLE, AMINOSALICYLIC ACID, ISONIAZID,
PYRAZINAMIDE, ACETAMINOPHEN, 3-METHYLCHOLANTHRENE, BETA-NAPHTHOFLAVONE,
ALPHA-NAPHTHOFLAVONE, 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN
SV0567153R5RU T CP Total protein
increase
CARMUSTINE, N,N-DIMETHYLFORMAMIDE, KETOCONAZOLE, AZATHIOPRINE,
CYPROTERONE ACETATE, PREDNISOLONE, PYROGALLOL, CORTISONE, ETHISTERONE,
MEGESTROL ACETATE, BETAMETHASONE, FLUDROCORTISONE ACETATE, ETHYLESTRENOL,
HYDROCORTISONE
SV0635003R5RU T CP Leukocyte count
increase
IBUPROFEN, 1-NAPHTHYL ISOTHIOCYANATE, BROMHEXINE, GENTIAN VIOLET,
CHLOROXYLENOL, NYSTATIN, PRAMOXINE, TICRYNAFEN, BENZETHONIUM CHLORIDE
SV0562020R5RU T CP Hemoglobin
decrease
IBUPROFEN, SULINDAC, DEXAMETHASONE, THIOGUANINE, NIMESULIDE, HYDROXYUREA,
CYTARABINE, INDOMETHACIN, DICLOFENAC, MELOXICAM, SULFISOXAZOLE,
LIPOPOLYSACCHARIDE E. COLI O55:B5, TRICHLOROACETIC ACID, PYROGALLOL,
ETODOLAC, BROMFENAC, KETOROLAC, PIOGLITAZONE, BENOXAPROFEN
SV0643003R5RU T BO Relative liver
weight decrease
SIMVASTATIN, ATORVASTATIN, DICLOFENAC, TAMOXIFEN, TOSUFLOXACIN, LOMEFLOXACIN,
3-METHYLCHOLANTHRENE, BETA-NAPHTHOFLAVONE, ALPHA-NAPHTHOFLAVONE, 2,3,7,8-
TETRACHLORODIBENZO-P-DIOXIN, CYCLOPROPANE CARBOXYLIC ACID
SV0562050R5RU T CP Alkaline phosphatase
decrease
SODIUM ARSENITE, KETOCONAZOLE, METHOTREXATE, MITOMYCIN C, ETODOLAC,
KETOROLAC, CYCLOPROPANE CARBOXYLIC ACID, ROFLUMILAST
SV0643002R5RU T BO Relative spleen
weight decrease
CHLORAMBUCIL, DEXAMETHASONE, THIOGUANINE, ROSIGLITAZONE, DOXORUBICIN,
LEFLUNOMIDE, KETOCONAZOLE, METHOTREXATE, BETAMETHASONE, HYDROCORTISONE,
EPIRUBICIN, FLUOCINOLONE ACETONIDE, DAUNORUBICIN, CYCLOPROPANE CARBOXYLIC
ACID
SV0562014R5RU T CP Mean corpuscular hemo-
globin decrease (diag-
nostic, 3–7D time points)
ETODOLAC, ROXITHROMYCIN, 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN, 3-
METHYLCHOLANTHRENE, PHENOBARBITAL, BETA-NAPHTHOFLAVONE, CYCLOPROPANE
CARBOXYLIC ACID
SV0562026R5RU T CP Leukocyte count
decrease
CHLORAMBUCIL, VALPROIC ACID, THIOGUANINE, CYTARABINE, DOXORUBICIN,
LEFLUNOMIDE, IFOSFAMIDE, CARMUSTINE, METHOTREXATE, PROCARBAZINE, MITOMYCIN
C, INDOMETHACIN, ETODOLAC, EPIRUBICIN, DAUNORUBICIN, CYCLOPROPANE
CARBOXYLIC ACID
SV0650033R5RU T H Liver-periportal,
hypertrophy
DEXAMETHASONE, ZOMEPIRAC, DICLOFENAC, MELOXICAM, MITOMYCIN C,
INDOMETHACIN, MESTRANOL, ETODOLAC, KETOROLAC, CARVEDILOL, EPIRUBICIN
SV0567174R5RU T CP Absolute basophil
increase
3-METHYLCHOLANTHRENE, BETA-NAPHTHOFLAVONE, ALPHA-NAPHTHOFLAVONE, 2,3,7,8-
TETRACHLORODIBENZO-P-DIOXIN, PERHEXILINE, ETHYLESTRENOL, CELECOXIB,
ROFECOXIB, BENOXAPROFEN
SV0642001R5RU T BO Relative liver
weight increase
DEXAMETHASONE,ITRACONAZOLE,KETOCONAZOLE,CYPROTERONE ACETATE, ARTEMISININ,
GENTIAN VIOLET, BETAMETHASONE, HYDROCORTISONE, FLUOCINOLONE ACETONIDE
SV0651106R5RU T H Liver-diffuse,
cytoplasm, eosinophilia
BEZAFIBRATE, FENOFIBRATE, FLUVASTATIN, CERIVASTATIN, ERYTHROMYCIN,
AMINOSALICYLIC ACID, PIRINIXIC ACID, VINBLASTINE
SV0575020R5RU T CP Lipase increase ATORVASTATIN, BISPHENOL A, KETOCONAZOLE, CLOTRIMAZOLE, BITHIONOL,
FLUVASTATIN, NITRAZEPAM
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and protein-DNA interaction [14,15,16,17,18,19,20,21,22,
23,24,25,26].
In this research, we present a classification of the liver
toxicogenomic data [27] to support decision making of drug
classification, or biomarkers when a new compound is entered
for examination. The following sections will describe the
microarray data obtained for the study, the analytical machine
learning method which include the classification model and
feature selection approach mRMR (Minimum-Redundancy-
Maximum-Relevance), the results of the prediction and some
discussions.
Materials and Methods
Original Data Set
The data used in this work are the time-series microarray data
that are extracted from a large liver xenobiotic and pharmaco-
logical response database of Iconix Biosciences. The data are
publicly available at GEO http://www.ncbi.nlm.nih.gov/geo
under accession number GSE8858. The initial data set consists
of 1695 individual animal studies and 5288 microarrays. GE
Healthcare/Amersham Biosciences CodeLink UniSet Rat I
Bioarray, layout EXP5280X2-584, layout EXP5280X2-613 and
layout EXP5280X2-648 containing about 10000 probes was used
to analyze the global gene expression in the livers of compound-
treated rats. Only treatments with gene expression data of day 1, 3
and 5 were involved in our analysis, including 402 treatments with
306 compounds.
Data Construction
First, we get a list of 10399 common probe sets between GE
Healthcare/Amersham Biosciences CodeLink UniSet Rat I Bioar-
ray, layout EXP5280X2-584, layout EXP5280X2-613 and layout
EXP5280X2-648. Secondly, the gene expression profiles of 402
treatments on day 1, 3 and 5 were obtained from corresponding 3563
microarrays by averaging the duplicated experiments. Then, the
control probe sets and probe sets without GenBank Accession
number were excluded. The probe sets with more than 30% missing
value were also excluded. This yields a subset of 9852 probes. After
probe filtering, the missing expression data were imputed using
nearest neighbor averaging. Finally, we normalized the expression
data of 402 treatments on day 1, 3 and 5 using quantile method.
Thus expression data of 9852 genes of each day (day 1, 3 or 5)
were involved in our study, producing 9852*3=29556 features for
each of the 402 samples. Each sample is to be allocated into the 34
categories listed in Table 1, with the allowance of multiple entries
into the categories, using the 29556 features.
Minimum Redundancy Maximum Relevance Feature
Selection
Minimum-Redundancy-Maximum-Relevance (mRMR) [28] is
a widely used method for feature selection. The goal of mRMR is
Unique ID Type Category Description Drugs
SV0571053R5RU T CP Absolute lymphocyte
decrease
CHLORAMBUCIL, THIOGUANINE, DEXAMETHASONE, DOXORUBICIN, KETOCONAZOLE,
BETAMETHASONE, FLUDROCORTISONE ACETATE, HYDROCORTISONE, EPIRUBICIN,
FLUOCINOLONE ACETONIDE, DAUNORUBICIN
SV0650143R5RU T H Liver-periportal,
fibrosis
1-NAPHTHYL ISOTHIOCYANATE, CARMUSTINE, LOMUSTINE, 4,49-METHYLENEDIANILINE,
CROTAMITON
SV0562116R5RU T CP Glucose decrease 1-NAPHTHYL ISOTHIOCYANATE, CLOTRIMAZOLE, NALOXONE, BETA-NAPHTHOFLAVONE,
ALPHA-NAPHTHOFLAVONE
SV0650106R5RU T H Liver- hepatocyte, peri-
portal, lipid accumulation
MICONAZOLE, ECONAZOLE, MIFEPRISTONE, ALPHA-NAPHTHOFLAVONE
SV0650121R5RU T H Liver- hepatocyte, centri-
lobular, lipid accumulation,
microvesicular
SULINDAC, MICONAZOLE, INDOMETHACIN, CHLOROFORM
SV0599196R5RU P SAC GR-MR agonist DEXAMETHASONE, PREDNISOLONE, CORTISONE, BETAMETHASONE, FLUDROCORTISONE
ACETATE, HYDROCORTISONE, FLUOCINOLONE ACETONIDE
SV0614125R5RU T SAC Toxicant, DNA
alkylator
N-NITROSODIETHYLAMINE, HYDRAZINE, 2-ACETYLAMINOFLUORENE, 4,49-
METHYLENEDIANILINE, AFLATOXIN B1, N-NITROSODIMETHYLAMINE
SV0614137R5RU P SAC Estrogen receptor
agonist, steroidal
ETHINYLESTRADIOL, BETA-ESTRADIOL, BETA-ESTRADIOL 3-BENZOATE, ESTRIOL,
MESTRANOL
SV0614148R5RU P SAC PPAR a agonist, fibric acid GEMFIBROZIL, BEZAFIBRATE, CLOFIBRIC ACID, PIRINIXIC ACID, NAFENOPIN
SV0599539R5RU P SAC H+/K+ ATPase inhibitor OMEPRAZOLE, PANTOPRAZOLE, LANSOPRAZOLE, RABEPRAZOLE
SV0614270R5RU P SAC PDE4 inhibitor PICLAMILAST, ROFLUMILAST, ROLIPRAM, SCH-351591
SV0599291R5RU T SAC Toxicant, heavy metal (3, 5
and 7D, other non- metal
toxicants in negative class)
SODIUM ARSENITE, LEAD(IV) ACETATE, LEAD (II) ACETATE
SV0614202R5RU T SAC Toxicant, heavy metal (0.25–
7D allowed, other toxicants
not in negative class)
SODIUM ARSENITE, LEAD (II) ACETATE, LEAD(IV) ACETATE
SV0614084R5RU P SAC HMG-CoA reductase inhibitors ATORVASTATIN, FLUVASTATIN, CERIVASTATIN
The ‘‘type’’ column indicates the toxicity-type (T) or the pharmacology-type (P); there are four categories of responses presented, body and organ weight (BO),
histopathology (H), clinical pathology (CP) and structure activity class (SAC).
doi:10.1371/journal.pone.0008126.t001
Table 1. Cont.
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property of a target classification variable, subject to the constraint
that these features are mutually as dissimilar to each other as
possible, but marginally as similar to the classification variable as
possible.
The feature which has maximum relevance with the target
variable and minimum redundancy within the features is defined
as a ‘‘good’’ feature. Mutual information (MI) is defined to
describe both relevance and redundancy:
I(x,y)~
ð ð
p(x,y)log
p(x,y)
p(x)p(y)
dxdy ð1Þ
Where x and y are two vectors; p(x,y) is the joint proba-
bilistic density; p(x) and p(y) are the marginal probabilistic
densities.
The whole vector set is defined as V, The selected vector set
with m vectors is defined as Vs, and the to-be-selected vector set
with n vectors is defined as Vt. Relevance D of a feature f in Vt
can be calculated by Eq (2):
D~I(f,c) ð2Þ
Here c is a classification variable.
Redundancy R of a feature f in Vt with all the features in Vs
can be calculated by Eq (3):
R~
1
m
X
fi[Vs
I(f,fi) ð3Þ
mRMR function maximize relevance and minimize redundancy
by integrating Eq (2) and Eq (3):
max
fj[Vt
I(fj,c){
1
m
X
fi[Vs
I(fj,fi)
"#
(j~1,2,:::,n) ð4Þ
After the pre-evaluation procedure, a feature set S is provided:
S~ f0
0
,f1
0
,:::,fh
0
,:::,fN{1
0 hi
ð5Þ
the feature index reflects the evaluations for feature. The
feature which fits the Eq(4) better will be added to the set S
earlier. For example, If a,b, fa is considered to be better
than fb.
Prediction Model
With the mRMR selected features, Nearest Neighbor Algorithm
(NNA) [29] is used to classify the data into the above mentioned
categories. NNA allocates a new data into categories by comparing
the features of the data with the features of those that have known
categories. The similarity between two vectors px, py is defined as
[25]:
D(px,py)~1{
px:py
jjpxjj:jjpyjj
ð6Þ
where px:py is the inner product of px and py, and ||p|| is the
module of vector p. px and py are considered to be more similar if
D(px,py) is smaller.
Traditionally, NNA chooses to classify the new pattern pt into
the class of its nearest neighbor which has the smallest D(pn,pt).
That is:
D(pn,pt)~minfD(p1,pt),D(p2,pt),:::,D(pz,pt),:::,D(pN,pt)g
(z=t)
ð7Þ
where N represents the number of training samples.
Because this research is about multi-target classification i.e. a
data can belong to more than one category, the prediction model
needs to be adjusted to cope with the multi-target problem. In the
prediction of multi-targets, if D(pm,pt),D(pn,pt), it means that pt is
closer to pm than to pn. Thus we rank the predicted classes of each
drug data as:
class iƒclass j if D(pi,pt)ƒD(pj,pt)
D(pi,pt)~minfD(p1,pt),D(p2,pt),:::,D(pZ,pt),:::D(pN,pt)g
(z=t,pz[class i)
ð8Þ
From Eq. (8), we can get a list with the most likely class (defined as
order-1 response) to be in the first position, and the second likely
class (defined as order-2 response) to be in the second position, and
so on.
Jackknife Cross-Validation Method
Jackknife Cross-Validation Method [14,18] is an effective and
objective way to evaluate statistical predictions. Each sample in the
data set is in turn knocked out and tested by the predictor trained
by the other samples remaining in the data set. During the process,
every sample is used not only for the training, but also for the
testing. The prediction accuracy Q for overall samples was used to
evaluate the performance of predictor:
Q~
TPzTN
TPzTNzFPzFN
ð9Þ
where TP, TN, FP and FN stand for true positive, true negative,
false positive and false negative, respectively.
Incremental Feature Selection (IFS)
mRMR only provides a list of features by sorting the features
according to their importance to the prediction without telling
how many fore features in the list should be selected. The fore
features are selected by testing all possible feature sets, and
choosing the feature set that achieves the best prediction rate. A
possible feature subset Si can be expressed by the following
equation.
Si~ff0,f1,:::,fig(0ƒiƒN{1) ð10Þ
The initial feature subset is S0~ff0g, and the last feature subset is
SN{1~ff0,f1,:::,fN{1g which includes all the features. Jackknife
test is then used to obtain the accurate prediction rates of all the
feature subsets. The one that achieves the highest prediction
accuracy is considered to be optimized feature set selected by IFS.
We can plot a curve, called IFS curve, with index i as its x-axis and
the overall accurate rate as its y-axis.
Results
IFS Curves of the Drug Responses
Because a drug may have several pharmaceutical responses, Eq.
8 is used to rate all the available responses. We only take the first
Predict Drug Responses
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are needed in a future research. The cumulated prediction
accuracies of first one, two, and three responses using different
number of features, are shown in Figure 1, evaluated by jackknife
cross-validation test. The highest prediction accuracy of first order
response was 63.9% with 141 features. The highest cumulated
prediction accuracies of first two responses and first three
responses were also achieved with these 141 features. The detailed
information of the IFS procedure and these 141 features can be
found in Table S1 and Table S2.
IFS Feature Selection and the Prediction Accuracy
141 features are selected as the result according to the IFS
curves. Using these 141 features, the highest prediction accuracy
for the first order response is 63.9%, evaluated by jackknife cross-
validation test. Unfortunately, the prediction accuracy is rather
low, which might be due to the sparse data points in the high-
dimensional feature space. More samples could be used in a future
research to study how much the prediction accuracy is affected by
the number of samples available for training and predicting the
prediction model. And the biological relevance of these 141
features was explored by KEGG and GO category enrichment
analysis.
The KEGG category enrichment analysis (see Table S3) shows
that two of the 141 features, Cyp3a9 and Ephx1, involves in the
pathway for the metabolism of xenobiotics by cytochrome P450.
Cytochrome P450s (CYP), comprising a superfamily of heme-
thiolate proteins, is the main metabolizing enzyme system for
foreign compounds, including drugs, and has a primary role in
organism protection against potential harmful assaults from the
environment [30]. It is often used as biomarker to determine
human exposure to environmental molecules or to predict the
susceptibility to certain pathologies [31,32].
The GO category enrichment analysis results (see Table S4,
Table S5 and Table S6) show that many of these candidate
biomarkers are involved in insulin signaling pathway. The
insulin-mediated receptor tyrosine kinase (RTK) signaling
pathways [33,34] by downstream effectors such as phosphati-
dylinositol 3-kinase, mitogen activated protein kinase (MAPK),
Akt/protein kinase B (PKB), mammalian target of rapamycin
(mTOR), and the p70 ribosomal protein S6 kinase (p70S6
kinase) have been reviewed [35] in the regulation of drug
metabolizing enzyme expression in response to insulin and
growth factors. The term fatty acid metabolism, comprising
genes such as fatty acid synthase, enoyl-CoA hydratase, acyl-
CoA synthetase among others is also enriched. The liver is a
major site for fatty acid and lipid metabolism, and several
major classes of compounds appearing in the database (statins,
fibrates, glitazones, estrogen receptor modulators and others)
affect the lipid synthesis and degradation. Fatty acids are a
major energy source and important constituents of membrane
lipids, and they serve as cellular signaling molecules that play
an important role in the etiology of the metabolic syndrome
[36]. Some liver samples exhibited elevated triglyceride levels
that were correlated with changes in the urinary associated with
defective metabolism of fatty acids, confirmed by the in vitro
experiments [37].
Figure 1. The IFS curve of first three responses prediction. The order-1 response is the most possible response according to the prediction.
The highest prediction accuracy of first order response was 63.9% with 141 features. The highest cumulated prediction accuracies of first two
responses and first three responses were also achieved with these 141 features. The red color points represent the highest accuracy points of each
kind of accuracy.
doi:10.1371/journal.pone.0008126.g001
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Microarray gene expression profiles has been proved valuable in
numerous applications including disease classification, diagnosis,
survival analysis, choice of therapy etc [38], but rarely used for
drug response prediction. The Connectivity Map [39,40] was a
new tool for finding connections among small molecules sharing a
mechanism of action, chemicals and physiological processes, and
diseases and drugs. But it couldn’t systematically research drug
response, because the reference collection of gene-expression
profiles in Connectivity Map were from cultured human cells
treated with bioactive small molecules and most cells were cancer
cell lines. The dataset we used were from in vivo rat liver which is
closer to clinic. The compound-treated rats had same background.
The bias in our research was much smaller. In the dataset of our
research, the small molecules were well organized and all the
responses were explicit recorded. There were thirty-four distinct
pharmacological and toxicological responses. In meta-dataset like
Connectivity Map’s reference collection, each experiment only
provided the phenotype this research group was interested in;
other responses were ignored in most time.
The statistic basis of Connectivity Map wasn’t solid [40]. The
methods we used like mRMR and NNA have solid statistic basis
and have been widely used in machine learning studies for a long
time. The results were proved effective strictly using Jackknife
Cross-Validation.
This paper presents a multi-target prediction for pharmacolog-
ical and xenobiotic responses from drugs, i.e. allocating a drug
treatment to several responses. Microarray data from liver
xenobiotic and pharmacological responses are adopted for the
prediction. Each drug treatment is coded by the genes of the
treated subjects, derived from the microarray profile, resulting in
thousands of features. Then mRMR method and IFS are used to
select a compact feature set (141 features) for the reduction of
feature dimension and improvement of prediction performance.
Finally, the features in the compact set, considered to be most
important for the prediction, are analyzed through GO category
enrichment analysis.
Supporting Information
Table S1 IFS prediction accuracy using different number of
features. The first column is the number of features used in
prediction. The following columns gave the prediction accuracies
from order-1 (the most possible response) to order-34 (the most
impossible response). The highest prediction accuracy of first order
response was 63.9% with 141 features.
Found at: doi:10.1371/journal.pone.0008126.s001 (0.32 MB
XLS)
Table S2 The detailed information of 141 features. The first
column is the feature name (probe name with time point). There
are 3 time points: day 1, 3 and 5 after treatment start. The third
column is the mRMR score.
Found at: doi:10.1371/journal.pone.0008126.s002 (0.12 MB
XLS)
Table S3 The KEGG enrichment of 141 features.
Found at: doi:10.1371/journal.pone.0008126.s003 (0.01 MB
XLS)
Table S4 The Gene Ontology Biological Process enrichment of
141 features.
Found at: doi:10.1371/journal.pone.0008126.s004 (0.07 MB
XLS)
Table S5 The Gene Ontology Molecular Function enrichment
of 141 features.
Found at: doi:10.1371/journal.pone.0008126.s005 (0.03 MB
XLS)
Table S6 The Gene Ontology Cellular Component enrichment
of 141 features.
Found at: doi:10.1371/journal.pone.0008126.s006 (0.02 MB
XLS)
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